Development and full validation of an LC–MS/MS methodology to quantify capmatinib (INC280) following intragastric administration to rats-Reference-Cited by-同舟云学术

Development and full validation of an LC–MS/MS methodology to quantify capmatinib (INC280) following intragastric administration to rats

Published:2020-01-17 Issue:3 Volume:34 Page:
ISSN:0269-3879
Container-title:Biomedical Chromatography
language:en
Short-container-title:Biomedical Chromatography

Author:

Fan Xiaoguang¹,Yang Guanghu¹,Cui Wenjuan¹,Liu Qin¹,Zhang Zhaolong¹,Zhang Zhikun¹^ORCID

Affiliation:

1. Intensive Care UnitShengli Oilfield Central Hospital Dongying China

Publisher

Wiley

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,General Medicine,Biochemistry,Analytical Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bmc.4768

Reference14 articles.

1. Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

2. Preliminary activity of capmatinib with gefitinib in NSCLC

3. Phase I dose‐escalation study of capmatinib ( INC 280) in Japanese patients with advanced solid tumors

4. Food and Drug Administration. (2018).Guidance for industry: bioanalytical method validation. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research and Center for Veterinary Medicine

5. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel disposable ultrasensitive sensor based on nanosized ceria uniformly loaded carbon nanofiber nanoceramic film wrapped on pencil graphite rods for electrocatalytic monitoring of a tyrosine kinase inhibitor capmatinib;Talanta;2024-11

2. Development and validation of an LC-MSMS method for the quantitation of pacritinib; application of kinetics in rabbits;Journal of Pharmacological and Toxicological Methods;2024-09

3. Development and validation of an ultra‐performance liquid chromatography–tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma;Biomedical Chromatography;2024-08-13

4. First electrochemical nanosensor for ultrasensitive quantification of MET inhibitor, capmatinib based on carbon nanofiber networks incorporated with hybrid nanofiller nanogold-loaded porous acetylene black;Microchemical Journal;2024-06

5. A Rapid and Sensitive UPLC-MS/MS Method for Quantifying Capmatinib in Human Liver Microsomes: Evaluation of Metabolic Stability by In Silico and In Vitro Analysis;Separations;2023-04-10